Steven Hearne, MD
Interventional Cardiology · Salisbury, MDNPI 1184616088
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,542 of the $100,063 with a category attached, or 83.5%. 37 manufacturers reported payments, led by Amgen at 60.0% of the total. Reporting peaked in 2019 at $31,080 and has fallen 60.2% since, to $12,371 in 2025. Among interventional cardiology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 668 payments — averaging $149.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$60K
- Novartis$15K
- Esperion Therapeutics, Inc.$11K
- Medtronic$3K
- Boehringer Ingelheim$3K
- Boston Scientific$2K
- plus $6K from 31 others
Across 393 payments — averaging $6405.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.2M
- Janssen Research & Development, LLC$599K
- Novartis$337K
- Kowa Research Institute, Inc.$130K
- Medtronic$78K
- Cathworks, Inc.$48K
- plus $134K from 9 others
What the payments were for
- Speaking & faculty fees$83,54283%
- Travel & lodging$9111%
- Food & beverage$15,46615%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 117 | $60,033 |
| Novartis | 97 | $15,320 |
| Esperion Therapeutics, Inc. | 17 | $10,654 |
| Medtronic(2 entities) | 62 | $3,387 |
| Boehringer Ingelheim | 41 | $2,697 |
| Boston Scientific | 84 | $1,633 |
| Abbott | 24 | $1,195 |
| AstraZeneca | 37 | $818 |
| Lilly USA, LLC | 1 | $675 |
| Johnson & Johnson | 35 | $538 |
| Edwards Lifesciences | 11 | $424 |
| E.r. Squibb & Sons, L.L.C. | 19 | $324 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $321 |
| Pfizer | 18 | $314 |
| Cardiovascular Systems Inc. | 6 | $228 |
| Chiesi USA, Inc. | 6 | $170 |
| Scpharmaceuticals Inc. | 10 | $166 |
| Merck | 10 | $146 |
| Novo Nordisk | 8 | $138 |
| Bayer | 7 | $119 |
| Regeneron Healthcare Solutions, Inc. | 4 | $86 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $85 |
| Lexicon Pharmaceuticals, Inc. | 4 | $78 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Amarin Pharma, Inc. | 3 | $65 |
| Cardinal Health 200 LLC | 5 | $63 |
| Alnylam Pharmaceuticals Inc. | 3 | $59 |
| Cvrx, Inc. | 2 | $53 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Biosense Webster, Inc. | 1 | $30 |
| Cardiva Medical, Inc. | 2 | $29 |
| Gilead | 2 | $26 |
| Atricure, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Teleflex LLC | 1 | $12 |
| Amryt Pharma Holdings Ltd | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$58,411
- ENTRESTO$13,492
- NEXLIZET$10,342
- NEXLETOL$10,342
- JARDIANCE$2,475
- CoreValve Evolut$1,125
- COREVALVE EVOLUT R$300
- MitraClip$260
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$143
- WATCHMAN Access System$134
- Diamondback Coronary$133
- Resolute$132
- TRICLIP$129
- Watchman$124
- LEQVIO$119
- KENGREAL$116
- ONYX FRONTIER$114
- FARXIGA$111
- AURORA EV-ICD MRI SURESCAN$110
- XIENCE SKYPOINT$100
How this compares
$100,063 in reported general payments places this provider in the 90th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $155,779 |
| EntrestoSacubitril/Valsartan | 49 | $60,314 |
| XareltoRivaroxaban | 26 | $40,103 |
| Repatha SureclickEvolocumab | 33 | $30,610 |
| JardianceEmpagliflozin | 29 | $28,135 |
| OzempicSemaglutide | 14 | $16,501 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 217 | $9,786 |
| Rosuvastatin Calcium | 212 | $6,707 |
| Ezetimibe | 131 | $6,042 |
| Atorvastatin Calcium | 233 | $4,358 |
| Metoprolol Succinate | 164 | $2,955 |
| Amiodarone Hcl | 53 | $2,928 |
| Nifedipine ErNifedipine | 101 | $2,859 |
| Valsartan | 59 | $2,623 |
| Labetalol Hcl | 61 | $2,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $314 | $155,779136 claims |
| NovartisEntresto | $15,320 | $60,31449 claims |
| Johnson & JohnsonXarelto | $538 | $40,10326 claims |
| Boehringer IngelheimJardiance, Pradaxa | $2,697 | $30,49440 claims |
| Novo NordiskOzempic | $138 | $16,50114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Salisbury
- Joseph CinderellaSalisbury$72K
- Jeffrey EthertonSalisbury$11K
- Mark TreuthSalisbury$8K
- Christian BoundsSalisbury$7K
- Vinay SatwahGreenbelt$679K
- Aloke FinnBaltimore$575K
- Michael ChenRockville$241K
- John WangBaltimore$138K
- Amir NajafiBel Air$82K
- Diljon ChahalBaltimore$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.